Table 1.
List of primers used in RT-qPCR experiments.
Fig 1.
Human skin grafts in a humanized mouse model.
(A) Macroscopic images of two examples of human skins (up and down panels) grafted onto the back of two immunocompromised Nude mice at different time points. (B) Measures of human skin graft thickness at different time points. (C) Quantification of collagen content in skin grafts at euthanasia. Results are expressed as the mean ± SEM (standard deviation of the mean), n = 5/group. *p<0.05, **p<0.01, ***p<0.001.
Fig 2.
Hypertrophic scar formation in a humanized mouse model.
(A) Masson’s trichrome staining of control human skin grafts (Ctrl; left) or hypertrophic scar (HTS; right) at week 8. Pictures focused on epidermis (upper panels) and dermis (lower panels) at same magnification (scale bar is 100 μm). (B) Immunohistochemical staining of HTS skins using antibodies specific for human pan-cytokeratin (upper left panel), human cytokeratin 5/6 (lower left panel), human involucrin (upper right panel) (scale bar is 250 μm). Immunofluorescence using an antibody specific for α-Sma (lower right panel) (magnification x40). Arrow indicated the demarcation between human (left) and mouse (right) tissues.
Fig 3.
Expression of fibrotic and remodelling markers in the hypertrophic scar humanized mouse model.
Measure of mRNAs of the indicated genes normalized to human YWHAZ expression in skin samples at weeks 8 and 9. Results are expressed as the mean ± SEM (standard deviation of the mean), n = 5/group. *p<0.05, **p<0.01.
Fig 4.
Reduction of hypertrophic scar after SVF or hASC injection in the hypertrophic scar humanized mouse model.
(A) Macroscopic images of human hypertrophic scar (HTS) grafted onto the back of immunocompromized Nude mice at week 7 (w7) at the time of cell injection (upper panels). Same HTS after injection of saline (Ctrl, left), SVF (middle) or hASCs (right) at weeks 8 and 9. (B) Measures of human skin graft thickness at different time points after saline, SVF or hASC injection. (C) Quantification of collagen content in skin grafts after saline, SVF or hASC injection and measured at euthanasia (weeks 8 or 9). Results are expressed as the mean ± SEM (standard deviation of the mean), n = 5/group. *p<0.05, **p<0.01.
Fig 5.
Histological evaluation of hypertrophic scar after SVF or hASC injection in the hypertrophic scar humanized mouse model.
(A) Masson’s trichrome staining of control hypertrophic scars injected with saline (HTS; left), SVF (middle) or hASCs (right) at weeks 8 (scale bar is 1 mm in upper panels and 100 μm in lower panels). (B) Same as in A) at week 9. (C) Quantification of epidermis and dermis thickness on histological sections of the grafts after saline, SVF or hASC injection and measured at euthanasia (weeks 8 or 9). (D) Fibrotic score evaluated on histological sections of groups described in C). Results are expressed as the mean ± SEM (standard deviation of the mean). n = 5/group (one experiment representative of two). *p<0.05.
Fig 6.
Expression of fibrotic, remodelling and inflammatory markers after SVF or hASC injection in the hypertrophic scar humanized mouse model.
(A) Measure of mRNAs of the indicated genes normalized to human YWHAZ expression in skin samples at week 8. Results are expressed as the mean ± SEM (standard deviation of the mean). n = 5/group. *p<0.05, **p<0.01. (B) Representative pictures of α-Sma positive areas in skin grafts after saline, SVF or hASC injection at week 8 by immunofluorescence staining.